15 September 2022 
EMA/CHMP/765087/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Biktarvy 
bictegravir / emtricitabine / tenofovir alafenamide 
On 15 September 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Biktarvy. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC. 
The CHMP adopted the addition of a new strength (30 mg/120 mg/15 mg, film-coated tablet) and an 
extension to the existing indication for Biktarvy to include the treatment of paediatric patients from 2 
years of age.  
For information, the full indication will be as follows:2  
Biktarvy is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in 
adults and paediatric patients at least 2 years of age and weighing at least 14 kg without 
present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or 
tenofovir (see section 5.1) 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
